Previous Clinical Trial Results
Haduvio™ – The First and Only Oral Therapy to Achieve Primary Endpoint in Treating Chronic Cough in IPF
of IPF Patients Experience Chronic Cough
Phase 2a Cough And NALbuphine (CANAL) Trial
We also measured cough reduction over a 24-hour period and the data also demonstrated a significant reduction in cough similar to the daytime measurement.
Current Clinical Trials
Based on the strength and consistency of these results, we initiated a Phase 2a trial in refractory chronic cough and a Phase 2b trial in IPF patients with chronic cough.